Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

HLI vs NMR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NMR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 9–1 Matrix Metrics)

NMR Overall Winner 6-Pillar Tally: HLI 2 – 3 NMR (1 Tie) Matrix Metrics: HLI 1 – 9 NMR

As of Nov 17, 2026, Nomura Holdings, Inc (NMR) is the stronger overall head-to-head candidate over Houlihan Lokey, Inc. (HLI) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HLI carries a Unified Composite Score of 37.0/100 (SELL) at $137.66 (16.6x Forward P/E, 22.8% operating margin), whereas NMR carries 44.5/100 (HOLD) at $9.34 (12.7x Forward P/E, 25.1% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HLI vs NMR
HLI NYSE
Houlihan Lokey, Inc.
Investment Advice
$137.66
-2.62% 1D
Market Cap $9.9B
TTM Revenue $2.56B
Forward P/E 16.6x
Beta / 30D Vol 0.71β · 41% Vol
Unified Composite Score
37.0 / 100 SELL
Tech 20.0 Fund 44.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 48.9 · SMA20: $141.02 · SMA50: $134.35
NMR NYSE Head-to-Head Winner
Nomura Holdings, Inc
Security Brokers, Dealers & Flotation Companies
$9.34
-1.68% 1D
Market Cap $28.3B
TTM Revenue $14.9B
Forward P/E 12.7x
Beta / 30D Vol 1.03β · 29% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 47.0 Fund 49.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.5 · SMA20: $9.40 · SMA50: $9.68

6-Pillar Scorecard Institutional Category Breakdown (HLI 2 – 3 NMR)

Columns: Metric · HLI · NMR
1. Valuation Multiples NMR
Forward P/E 16.6x 12.7x
Trailing P/E 24.0x 11.2x
PEG Ratio 6.54x 0.81x
EV / Revenue 3.9x 1.9x
2. Growth & Scale NMR
Revenue Growth (YoY) +4.8% +17.9%
Earnings Growth (YoY) +0.4% +13.6%
TTM Revenue (USD) $2.56B $14.9B
Market Cap $9.9B $28.3B
3. Profitability & Quality NMR
Gross Margin 94.0% 77.4%
Operating Margin 22.8% 25.1%
Net Profit Margin 15.8% 17.1%
Return on Equity (ROE) 17.3% 11.5%
4. Balance Sheet & Cash Flow HLI
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $33.24 Book/Sh · 17.3% ROE $8.17 Book/Sh · 11.5% ROE
Dividend Yield 1.81% 3.34%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 26.0% (2nd %ile) 30.7% (<1st %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat HLI
OpEx & R&D Intensity 71.2% of Rev ($1.82B) 52.3% of Rev ($7.77B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Capital Markets Operator Capital Markets Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HLI (1) vs NMR (9)
Institutional Metric HLI NMR Criterion Row Edge
Market Capitalization
Scale
$9.9B $28.3B Larger Scale NMR
Trailing P/E Ratio
Valuation
24.0x 11.2x Lower Multiple NMR
Forward P/E Ratio
Valuation
16.6x 12.7x Lower Multiple NMR
Revenue Growth (YoY)
Growth
+4.8% +17.9% Higher Growth NMR
Operating Margin (TTM)
Profitability
22.8% 25.1% Higher Margin NMR
Net Profit Margin
Profitability
15.8% 17.1% Higher Margin NMR
Return on Equity (ROE)
Capital Efficiency
17.3% 11.5% Higher ROE HLI
52-Week Range Position
Momentum
30% ($113–$195) 61% ($7–$11) Stronger Trend NMR
Beta / 30D Volatility
Risk Regime
0.71β · 41% Vol 1.03β · 29% Vol Lower Realized Risk NMR
Unified Institutional Score
Composite Signal
37.0 / 100 (SELL) 44.5 / 100 (HOLD) Higher Composite NMR
Trailing 12M Revenue (USD)
Operating Scale
$2.56B $14.9B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.0% 77.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
6.54x PEG · 3.9x EV/Rev 0.81x PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($33.24 Book/Sh · 17.3% ROE) N/A ($8.17 Book/Sh · 11.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HLI +5.92 pp
HLI: +8.33% · NMR: +2.41%
3M Horizon HLI +7.61 pp
HLI: +5.82% · NMR: -1.79%
6M Horizon NMR +22.98 pp
HLI: -6.23% · NMR: +16.75%
1Y Horizon NMR +49.91 pp
HLI: -23.52% · NMR: +26.39%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HLI vs NMR. Trailing 12-month operating profitability (HLI 22.8% vs NMR 25.1%) and valuation multiples (HLI 16.6x vs NMR 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.

HLI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.56B
Gross Margin94.0%
Op. Margin22.8%
ROE / Fwd P/E17.3% · 16.6x
NMR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$14.9B
Gross Margin77.4%
Op. Margin25.1%
ROE / Fwd P/E11.5% · 12.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HLI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 26.0%
IV Percentile 2nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HLI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NMR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 30.7%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HLI Moat Profile Scale & Operating Efficiency Moat
Capital Markets Operator
Competes within the Capital Markets value chain with $9.9B market capitalization and 22.8% operating margin.
OpEx & R&D Reinvestment 71.2% of Rev ($1.82B)
90D Engineering Disclosures 0 Published
NMR Moat Profile Scale & Operating Efficiency Moat
Capital Markets Operator
Competes within the Capital Markets value chain with $28.3B market capitalization and 25.1% operating margin.
OpEx & R&D Reinvestment 52.3% of Rev ($7.77B)
90D Engineering Disclosures 0 Published

Investor FAQ HLI vs NMR Key Questions & Quantitative Answers

As of Nov 17, 2026, Nomura Holdings, Inc (NMR) is the stronger overall head-to-head candidate over Houlihan Lokey, Inc. (HLI) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HLI carries a Unified Composite Score of 37.0/100 (SELL) at $137.66 (16.6x Forward P/E, 22.8% operating margin), whereas NMR carries 44.5/100 (HOLD) at $9.34 (12.7x Forward P/E, 25.1% operating margin). Technically, HLI sits in a Neutral phase (RSI 48.9, UNCLASSIFIED options structure) and NMR sits in a Neutral phase (RSI 45.5, UNCLASSIFIED options structure).

NMR leads the Growth & Scale pillar: HLI posts +4.8% YoY revenue growth and +0.4% YoY earnings growth on $2.56B TTM revenue (94.0% gross margin, 22.8% operating margin), compared with NMR at +17.9% YoY revenue growth and +13.6% YoY earnings growth on $14.9B TTM revenue (77.4% gross margin, 25.1% operating margin). On trailing 12-month operating scale, HLI generates $2.56B in USD-normalized revenue versus $14.9B for NMR. In operating R&D and SG&A reinvestment, HLI deploys 71.2% of Rev ($1.82B) (0 90-day corporate R&D disclosures) versus 52.3% of Rev ($7.77B) (0 disclosures) for NMR.

NMR screens cheaper on headline valuation multiples. HLI trades at 16.6x Forward P/E, 24.0x Trailing P/E, 6.54x PEG, and 3.9x EV/Revenue (unreported cash flow margin), whereas NMR trades at 12.7x Forward P/E, 11.2x Trailing P/E, 0.81x PEG, and 1.9x EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HLI (17.3% ROE) versus NMR (11.5% ROE) capital efficiency.

In options market volatility and institutional positioning, HLI carries 26.0% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 41% Vol realized risk). By comparison, NMR carries 30.7% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.03β · 29% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.